Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05897541 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection
A Phase 3 study, sponsored by Shionogi.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,387
- Enrollment target
NCT05897541 is a Phase 3 study that has completed, run by Shionogi. The registered enrollment target is 2,387 participants.
The verdict
NCT05897541, a Phase 3 study, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,387 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (positive reverse transcription polymerase chain reaction \[RT-PCR\] test) and have coronavirus disease 2019 (COVID-19) symptom(s) with S-217622 tablets compared with placebo tablets in participants who are household contacts of an individual with symptomatic COVID-19.
Interventions
- DRUG Placebo
- DRUG S-217622
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,387 participants |
| Start Date | 2023-06-09 |
| Est. Completion | 2024-09-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05897541
The ClinicalTrials.gov registry entry for NCT05897541 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,387 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05897541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05897541 about?
NCT05897541 is a clinical study titled "Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection". The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (positive reverse transcription polymerase chain reaction \[RT-PCR\] test) and have coronavirus disease 2019 (COVID-19) symptom(s) with S-217622 t...
What is the current status of trial NCT05897541?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,387 participants. The study started on 2023-06-09. Estimated completion is 2024-09-18.
What interventions are being tested in trial NCT05897541?
The interventions under investigation include: Placebo (DRUG), S-217622 (DRUG).
Who is sponsoring clinical trial NCT05897541?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.